Have a personal or library account? Click to login
Impact of Intraoperative Cell Salvage on Circulating Tumor Cells and Cellular Activity in Patients with Hepatocellular Carcinoma Undergoing Curative Resection: A Prospective Comparative Study Cover

Impact of Intraoperative Cell Salvage on Circulating Tumor Cells and Cellular Activity in Patients with Hepatocellular Carcinoma Undergoing Curative Resection: A Prospective Comparative Study

Archivum Immunologiae et Therapiae Experimentalis
Volume 73 (2025): Issue 1 (January 2025)
By: Ke Yue,  Lai-wei You,  Bao-ji Hu,  Yong Cheng,  Jinhuo Wang,  Hao Li and  Jianrong Guo  
Open Access
|Jun 2025

Figures & Tables

Fig 1.

The apoptosis levels in patients with HCC from different groups were detected at preoperative, intraoperative, and postoperative six points using the ATP cell viability detection assays. ATP, adenosine triphosphate; HCC, hepatocellular carcinoma.
The apoptosis levels in patients with HCC from different groups were detected at preoperative, intraoperative, and postoperative six points using the ATP cell viability detection assays. ATP, adenosine triphosphate; HCC, hepatocellular carcinoma.

Fig 2.

The apoptosis levels in patients with HCC from different groups were detected at preoperative, intraoperative, and postoperative 6 h using flow cytometry assays. HCC, hepatocellular carcinoma.
The apoptosis levels in patients with HCC from different groups were detected at preoperative, intraoperative, and postoperative 6 h using flow cytometry assays. HCC, hepatocellular carcinoma.

Fig 3.

The CTCs in patients with HCC from different groups were detected at preoperative, intraoperative, and postoperative 6 h using an immunomagnetic bead separation combined with flow cytometry assays. CTCs, circulating tumor cell; HCC, hepatocellular carcinoma.
The CTCs in patients with HCC from different groups were detected at preoperative, intraoperative, and postoperative 6 h using an immunomagnetic bead separation combined with flow cytometry assays. CTCs, circulating tumor cell; HCC, hepatocellular carcinoma.

Fig 4.

The expression levels of AFP and GPC3 proteins in patients with HCC from different groups were determined at postoperative 6 h using Western blotting. HCC, hepatocellular carcinoma.
The expression levels of AFP and GPC3 proteins in patients with HCC from different groups were determined at postoperative 6 h using Western blotting. HCC, hepatocellular carcinoma.

Fig 5.

The expression levels of CTNNB1 and TP53 mRNA in patients with HCC from different groups were determined at preoperative and postoperative 6 h using the qRT-PCR. HCC, hepatocellular carcinoma.
The expression levels of CTNNB1 and TP53 mRNA in patients with HCC from different groups were determined at preoperative and postoperative 6 h using the qRT-PCR. HCC, hepatocellular carcinoma.

Fig 6.

The detection of EpCAM in patients with HCC from different groups at preoperative and postoperative 6 h time points, using an immunofluorescence assay. HCC, hepatocellular carcinoma.
The detection of EpCAM in patients with HCC from different groups at preoperative and postoperative 6 h time points, using an immunofluorescence assay. HCC, hepatocellular carcinoma.

Demographic, participants' general data

VariableExperimental group (N = 40)Control group (N = 40)χ2/tP
Gender, male (%)24 (60%)22 (55%)0.3310.565
Age (years)65.4 (50.3–73.8)64.8 (50.4–74.5)0.3190.750
BMI (kg/m2)26.5 (24.1–29.3)26.9 (23.2–30.5)−0.5360.594
Child-Pugh classification 0.3720.543
A26 (65%)24 (60%)
B14 (35%)16 (40%)
TNM stage 0.4920.78
I1820
II2019
III21
IV00
ALT (U/L)61.3 (41.1–82.3)61.8 (41.4–81.6)−0.1440.886
AST (U/L)56.2 (40.2–76.1)55.6 (40.6–77.3)0.2330.81
DOI: https://doi.org/10.2478/aite-2025-0015 | Journal eISSN: 1661-4917
Journal RSS Feed
Language: English
Submitted on: Dec 18, 2024
Accepted on: Mar 11, 2025
Published on: Jun 23, 2025
Published by: Hirszfeld Institute of Immunology and Experimental Therapy
In partnership with: Paradigm Publishing Services
Publication frequency: 1 issue per year
Keywords:
Intraoperative cell salvage,
Circulating tumor cell,
Hepatocellular carcinoma,
Cellular activity
Related subjects:
Medicine,
Basic medical science,
Biochemistry,
Immunology,
Clinical medicine,
Clinical medicine, other,
Clinical chemistry

© 2025 Ke Yue, Lai-wei You, Bao-ji Hu, Yong Cheng, Jinhuo Wang, Hao Li, Jianrong Guo, published by Hirszfeld Institute of Immunology and Experimental Therapy
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Previous articleVolume 73 (2025): Issue 1 (January 2025)Next article